Product Code: GVR-1-68038-833-6
Male Infertility Market Growth & Trends:
The global male infertility market size is expected to reach USD 5.9 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.9% from 2022 to 2030. Advancements in diagnostic tests and increasing infertility in males are some of the major factors driving the market for male infertility. In addition, lifestyle-associated diseases causing infertility, rising obesity, and the growing aging population are likely to boost the market growth during the forecast period. In the U.S., one-third of infertility cases are due to female factors, one-third due to male factors, and the remaining one-third of the cases are unknown.
The COVID-19 pandemic had a severe impact on healthcare services. The diagnostic kits and critical medical supplies witnessed growing demand. On the other hand, most elective medical procedures dropped by around 50%. As only emergency medical procedures were allowed during the initial phase of the pandemic, the market observed a decline.
DNA fragmentation technique emerged as the largest test segment in 2021 and is expected to maintain its lead during the forecast period. Increasing adoption in developed countries and high cost due to higher sensitivity and reliable analysis of sperm DNA integrity are the key factors driving the segment. The Assisted Reproductive Technology (ART) and varicocele surgery segment dominated the market for male infertility in 2021 due to its high success rate. Intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) are the most commonly used ARTs.
Partnerships and agreements among key manufacturers are expected to boost the market growth in the coming years. For instance, in July 2019, Vitrolife entered into a collaboration with Prime Tech for the development and exclusive marketing of the Piezo technique for improved Intracytoplasmic Sperm Injection (ICSI) procedure in human IVF globally except Malaysia, Thailand, and Japan. Additionally, Vitrolife will initiate the regulatory approval procedures in various markets for the future commercialization of the technology.
Male Infertility Market Report Highlights:
- Based on test, DNA fragmentation technique dominated the market in 2021 and is estimated to witness significant growth over the forecast period due to the higher accuracy of the test
- The oxidative stress analysis test segment is gaining popularity due to the accurate determination of reactive oxygen species. In March 2018, Aytu BioScience, Inc. received registration from COFEPRIS in Mexico for MiOXSYS System, which is used for diagnosing male infertility
- Europe dominated the market in 2021 and is expected to maintain its lead during the forecast period due to high adoption of costlier treatment, strong diagnosis rate, and increased awareness
- Asia Pacific is projected to witness substantial growth over the forecast period owing to increasing investment by several clinics and pharmaceutical companies and growing healthcare expenditure
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation & Scope
- 1.1.1 Test
- 1.1.2 Treatment
- 1.1.3 Regional Scope
- 1.1.4 Estimates and Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary research
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity flow analysis (Model 1)
- 1.6.2 Volume price analysis (model 2)
- 1.7 List of Secondary Sources
- 1.8 Objectives
- 1.8.1 Objective - 1
- 1.8.2 Objective - 2
Chapter 2 Executive Summary
- 2.1 Market Outlook
- 2.2 Segment Outlook
- 2.2.1 Test
- 2.2.2 Treatment
- 2.2.3 Region
- 2.3 Competitive Insights
- 2.4 Male Infertility Market Outlook, 2021
Chapter 3 Market Variables, Trends & Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.2 Market Segmentation
- 3.3 Penetration & Growth Prospect Mapping
- 3.3.1 Penetration Analysis
- 3.3.2 Market driver analysis
- 3.3.2.1 High Adoption of Assisted Reproductive Technology (ART)
- 3.3.2.2 Increasing incidence of infertility
- 3.3.2.3 Acquisitions, mergers, and partnerships in the market
- 3.3.2.4 Technological advancements
- 3.3.3 Market restraint analysis
- 3.3.3.1 High cost of treatment
- 3.4 Male Infertility Market: Business Environment Analysis Tools
- 3.4.1 Porter's Five Forces Analysis
- 3.4.2 PESTEL Analysis
- 3.5 Clinical Trial Analysis
Chapter 4 Male Infertility Market: Test Analysis
- 4.1 Male Infertility Test Market Share Analysis, 2021 & 2030
- 4.2 Male Infertility Test Market: Segment Dashboard:
- 4.3 Market Size & Forecasts and Trend Analyses, 2017 - 2030 for the Test Segment
- 4.3.1 DNA Fragmentation Technique
- 4.3.1.1 DNA fragmentation technique market, 2017 - 2030 (USD Million)
- 4.3.2 Oxidative Stress Analysis
- 4.3.2.1 Oxidative stress analysis market, 2017 - 2030 (USD Million)
- 4.3.3 Microscopic Examination
- 4.3.3.1 Microscopic Examination market, 2017 - 2030 (USD Million)
- 4.3.4 Sperm Agglutination
- 4.3.4.1 Sperm agglutination market, 2017 - 2030 (USD Million)
- 4.3.5 Computer Assisted Semen Analysis
- 4.3.5.1 Computer-assisted semen analysis market, 2017 - 2030 (USD Million)
- 4.3.6 Sperm Penetration Assay
- 4.3.6.1 Sperm penetration assay market, 2017 - 2030 (USD Million)
- 4.3.7 Others
- 4.3.7.1 Others market, 2017 - 2030 (USD Million)
Chapter 5 Male Infertility Market: Treatment Analysis
- 5.1 Male Infertility Treatment Market Share Analysis, 2021 & 2030
- 5.2 Male Infertility Treatment Market: Segment Dashboard:
- 5.3 Market Size & Forecasts and Trend Analyses, 2017 - 2030 for the Treatment Segment
- 5.3.1 ART & Varicocele Surgery
- 5.3.1.1 ART & varicocele surgery market, 2017 - 2030 (USD Million)
- 5.3.2 Medication
- 5.3.2.1 Medication market, 2017 - 2030 (USD Million)
Chapter 6 Male Infertility Market: Regional Analysis
- 6.1 Male Infertility Regional Market Share Analysis, 2021 & 2030
- 6.2 Male Infertility Regional Market: Segment Dashboard
- 6.3 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
- 6.4 SWOT Analysis, by Region
- 6.4.1 North America
- 6.4.2 Europe
- 6.4.3 Asia Pacific
- 6.4.4 Latin America
- 6.4.5 MEA
- 6.5 Market Size, & Forecasts, and Trend Analysis, 2017 - 2030
- 6.5.1 North America
- 6.5.1.1 North America male infertility market, 2017 - 2030 (USD Million)
- 6.5.1.1.1 U.S.
- 6.5.1.1.1.1 Regulatory & reimbursement scenario
- 6.5.1.1.1.2 U.S. male infertility market, 2017 - 2030 (USD Million)
- 6.5.1.1.2 Canada
- 6.5.1.1.2.1 Regulatory & reimbursement scenario
- 6.5.1.1.2.2 Canada male infertility market, 2017 - 2030 (USD Million)
- 6.5.2 Europe
- 6.5.2.1 Europe male infertility market, 2017 - 2030 (USD Million)
- 6.5.2.1.1 U.K.
- 6.5.2.1.1.1 Regulatory & reimbursement scenario
- 6.5.2.1.1.2 U.K. male infertility market, 2017 - 2030 (USD Million)
- 6.5.2.1.2 Germany
- 6.5.2.1.2.1 Regulatory & reimbursement scenario
- 6.5.2.1.2.2 Germany male infertility market, 2017 - 2030 (USD Million)
- 6.5.2.1.3 France
- 6.5.2.1.3.1 Regulatory & reimbursement scenario
- 6.5.2.1.3.2 France male infertility market, 2017 - 2030 (USD Million)
- 6.5.2.1.4 Italy
- 6.5.2.1.4.1 Regulatory & reimbursement scenario
- 6.5.2.1.4.2 Italy male infertility market, 2017 - 2030 (USD Million)
- 6.5.2.1.5 Spain
- 6.5.2.1.5.1 Regulatory & reimbursement scenario
- 6.5.2.1.5.2 Spain male infertility market, 2017 - 2030 (USD Million)
- 6.5.3 Asia Pacific
- 6.5.3.1 Asia Pacific male infertility market, 2017 - 2030 (USD Million)
- 6.5.3.1.1 Japan
- 6.5.3.1.1.1 Regulatory & reimbursement scenario
- 6.5.3.1.1.2 Japan male infertility market, 2017 - 2030 (USD Million)
- 6.5.3.1.2 China
- 6.5.3.1.2.1 Regulatory & reimbursement scenario
- 6.5.3.1.2.2 China male infertility market, 2017 - 2030 (USD Million)
- 6.5.3.1.3 India
- 6.5.3.1.3.1 Regulatory & reimbursement scenario
- 6.5.3.1.3.2 India male infertility market, 2017 - 2030 (USD Million)
- 6.5.4 Latin America
- 6.5.4.1 Latin America male infertility market, 2017 - 2030 (USD Million)
- 6.5.4.1.1 Brazil
- 6.5.4.1.1.1 Regulatory & reimbursement scenario
- 6.5.4.1.1.2 Brazil male infertility market, 2017 - 2030 (USD Million)
- 6.5.4.1.2 Mexico
- 6.5.4.1.2.1 Regulatory & reimbursement scenario
- 6.5.4.1.2.2 Mexico male infertility market, 2017 - 2030 (USD Million)
- 6.5.5 Middle East and Africa (MEA)
- 6.5.5.1 MEA male infertility market, 2017 - 2030 (USD Million)
- 6.5.5.1.1 South Africa
- 6.5.5.1.1.1 Regulatory & reimbursement scenario
- 6.5.5.1.1.2 South Africa male infertility market, 2017 - 2030 (USD Million)
Chapter 7 Competitive Analysis
- 7.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
- 7.2 Vendor Landscape
- 7.2.1 Strategy Mapping
- 7.2.2 Launch of New Products
- 7.2.3 Merger and Acquisition
- 7.2.4 Product Approvals
- 7.3 Company Market Position Analysis (Geographic Presence, Product Portfolio, Strategic Initiatives)
- 7.4 Company Profiles
- 7.4.1 EMD Serono, Inc.
- 7.4.1.1 Company overview
- 7.4.1.2 Financial performance
- 7.4.1.3 Product benchmarking
- 7.4.1.4 Strategic initiatives
- 7.4.2 Endo International plc
- 7.4.2.1 Company overview
- 7.4.2.2 Financial performance
- 7.4.2.3 Product benchmarking
- 7.4.2.4 Strategic initiatives
- 7.4.2.5 SWOT analysis
- 7.4.3 Sanofi
- 7.4.3.1 Company overview
- 7.4.3.2 Financial performance
- 7.4.3.3 Product benchmarking
- 7.4.3.4 Strategic initiatives
- 7.4.3.5 SWOT Analysis
- 7.4.4 Bayer Group
- 7.4.4.1 Company overview
- 7.4.4.2 Financial performance
- 7.4.4.3 Product benchmarking
- 7.4.4.4 Strategic initiatives
- 7.4.4.5 SWOT analysis
- 7.4.5 SCSA Diagnostics
- 7.4.5.1 Company overview
- 7.4.5.2 Product benchmarking
- 7.4.6 Andrology Solutions
- 7.4.6.1 Company overview
- 7.4.6.2 Product benchmarking
- 7.4.7 Halotech DNA SL
- 7.4.7.1 Company overview
- 7.4.7.2 Product benchmarking
- 7.4.7.3 Strategic initiatives
- 7.4.8 Intas Pharmaceuticals Ltd.
- 7.4.8.1 Company overview
- 7.4.8.2 Financial performance
- 7.4.8.3 Product benchmarking
- 7.4.8.4 Strategic initiatives
- 7.4.8.5 SWOT analysis
- 7.4.9 Aytu BioScience, Inc.
- 7.4.9.1 Company overview
- 7.4.9.2 Financial performance
- 7.4.9.3 Product Benchmarking
- 7.4.9.4 Strategic initiatives
- 7.4.9.5 SWOT Analysis
- 7.4.10 Cadila Pharmaceuticals
- 7.4.10.1 Company overview
- 7.4.10.2 Product benchmarking
- 7.4.10.3 Strategic initiatives
- 7.4.11 Vitrolife
- 7.4.11.1 Company overview
- 7.4.11.2 Financial performance
- 7.4.11.3 Product benchmarking
- 7.4.11.4 Strategic initiatives
- 7.4.11.5 SWOT Analysis
Chapter 8 Recommendations